Ontak is a CD25-directed cytotoxin indicated for the treatment fo patients with persistent or recurrent Cutaneous T- Cell Lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.

Subtype:

Lymphoma, T-Cell, Cutaneous (CTCL)

License:

FDA

Class:

IL-2 receptor inhibitor

R/R

PIhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103767s5119lbl.pdf 

1. Approved Labelling 

Ontak is indicated for the treatment fo patients with persistent or recurrent Cutaneous T- Cell Lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.

2. Treatment Regimen

Premedicate with an antihistamine and acetaminophen prior to each Ontak infusion. Administer at 9 or 18 mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.

3. AE/Warnings

Please see section 5 of the PI

 

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.